SIRPA
Tyrosine-protein phosphatase non-receptor type substrate 1
Also known as: BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SHPS1_HUMAN, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P78324
- Gene
- SIRPA
- Ensembl
- ENSG00000198053
- Chromosome
- 20
- Canonical length
- 504 aa
- Protein class
- CD markers, Plasma proteins, Predicted membrane proteins
OverviewNCBI Gene
The protein encoded by this gene is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP family members are receptor-type transmembrane glycoproteins known to be involved in the negative regulation of receptor tyrosine kinase-coupled signaling processes. This protein can be phosphorylated by tyrosine kinases. The phospho-tyrosine residues of this PTP have been shown to recruit SH2 domain containing tyrosine phosphatases (PTP), and serve as substrates of PTPs. This protein was found to participate in signal transduction mediated by various growth factor receptors. CD47 has been demonstrated to be a ligand for this receptor protein. This gene and its product share very high similarity with several other members of the SIRP family. These related genes are located in close proximity to each other on chromosome 20p13. Multiple alternatively spliced transcript variants have been determined for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
504 residues, UniProt reviewed canonical sequence.
>P78324|SIRPA
1 MEPAGPAPGR LGPLLCLLLA ASCAWSGVAG EEELQVIQPD KSVLVAAGET ATLRCTATSL
61 IPVGPIQWFR GAGPGRELIY NQKEGHFPRV TTVSDLTKRN NMDFSIRIGN ITPADAGTYY
121 CVKFRKGSPD DVEFKSGAGT ELSVRAKPSA PVVSGPAARA TPQHTVSFTC ESHGFSPRDI
181 TLKWFKNGNE LSDFQTNVDP VGESVSYSIH STAKVVLTRE DVHSQVICEV AHVTLQGDPL
241 RGTANLSETI RVPPTLEVTQ QPVRAENQVN VTCQVRKFYP QRLQLTWLEN GNVSRTETAS
301 TVTENKDGTY NWMSWLLVNV SAHRDDVKLT CQVEHDGQPA VSKSHDLKVS AHPKEQGSNT
361 AAENTGSNER NIYIVVGVVC TLLVALLMAA LYLVRIRQKK AQGSTSSTRL HEPEKNAREI
421 TQDTNDITYA DLNLPKGKKP APQAAEPNNH TEYASIQTSP QPASEDTLTY ADLDMVHLNR
481 TPKQPAPKPE PSFSEYASVQ VPRKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SIRPA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 160 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 160 nTPM
- cerebellum: 112 nTPM
- amygdala: 102 nTPM
- basal ganglia: 93 nTPM
- hippocampal formation: 83 nTPM
- midbrain: 52 nTPM
Single-cell type
- neutrophils: 801 nCPM
- monocytes: 215 nCPM
- neutrophil progenitors: 183 nCPM
- astrocytes: 160 nCPM
- hofbauer cells: 143 nCPM
- macrophages: 128 nCPM
Immune cell
- neutrophil: 51 nTPM
- eosinophil: 49 nTPM
- classical monocyte: 24 nTPM
- myeloid DC: 14 nTPM
- total PBMC: 9.9 nTPM
- intermediate monocyte: 6 nTPM
Brain region
- cerebral cortex: 245 nTPM
- amygdala: 227 nTPM
- basal ganglia: 222 nTPM
- thalamus: 206 nTPM
- hippocampal formation: 198 nTPM
- midbrain: 188 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.43
- gnomAD pLI
- 0.67
- gnomAD missense Z
- 1.06
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell adhesion
- cell migration
- cellular response to hydrogen peroxide
- cellular response to interleukin-1
- cellular response to interleukin-12
- cellular response to type II interferon
- monocyte extravasation
- negative regulation of canonical NF-kappaB signal transduction
- negative regulation of chemokine (C-C motif) ligand 5 production
- negative regulation of cytokine production involved in inflammatory response
- negative regulation of ERK1 and ERK2 cascade
- negative regulation of inflammatory response
- negative regulation of interferon-beta production
- negative regulation of interleukin-6 production
- negative regulation of JNK cascade
- negative regulation of lipopolysaccharide-mediated signaling pathway
- negative regulation of macrophage inflammatory protein 1 alpha production
- negative regulation of nitric oxide biosynthetic process
- negative regulation of phagocytosis
- negative regulation of tumor necrosis factor production
- positive regulation of phagocytosis
- positive regulation of reactive oxygen species metabolic process
- positive regulation of T cell activation
- regulation of gene expression
- regulation of interleukin-1 beta production
- regulation of interleukin-6 production
- regulation of nitric oxide biosynthetic process
- regulation of tumor necrosis factor production
- regulation of type II interferon production
Molecular functions
- cell-cell adhesion mediator activity
- GTPase regulator activity
- protein antigen binding
- protein binding involved in heterotypic cell-cell adhesion
- protein phosphatase binding
- protein phosphatase inhibitor activity
- protein tyrosine kinase binding
- SH3 domain binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SIRPA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SIRPA as an antibody target. Whether an autoantibody or antibody against SIRPA could matter depends on whether native SIRPA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SIRPA is annotated at the cell surface, where native SIRPA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SIRPA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...